Advertisement

Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis

Published:September 23, 2021DOI:https://doi.org/10.1016/j.jcf.2021.09.007

      Highlights

      • Historic cohorts suggested that supply of inhaled medicines may exceed actual use.
      • This is the first study to directly compare medicine supply (MPR) against adherence.
      • Among 275 adults in 12 CF centres, MPR over-estimates adherence by a median of 14%.
      • Even with 20% contingency, mean annual cost of excess supply was £1,124/patient.
      • Excess supply cost was higher in those with adherence <50% (mean £2,017/patient).

      Abstract

      Background

      Studies in separate cohorts suggest possible discrepancies between inhaled medicines supplied (median 50-60%) and medicines used (median 30-40%). We performed the first study that directly compares CF medicine supply against use to identify the cost of excess medicines supply.

      Methods

      This cross-sectional study included participants from 12 UK adult centres with ≥1 year of continuous adherence data from data-logging nebulisers. Medicine supply was measured as medication possession ratio (MPR) for a 1-year period from the first suitable supply date. Medicine use was measured as electronic data capture (EDC) adherence over the same period. The cost of excess medicines was calculated as whole excess box(es) supplied after accounting for the discrepancy between EDC adherence and MPR with 20% contingency.

      Results

      Among 275 participants, 133 (48.4%) were females and mean age was 30 years (95% CI 29-31 years). Median EDC adherence was 57% (IQR 23-86%), median MPR was 74% (IQR 46-96%) and the discrepancy between measures was median 14% (IQR 2-29%). Even with 20% contingency, mean potential cost of excess medicines was £1,124 (95% CI £855-1,394), ranging from £183 (95% CI £29-338) for EDC adherence ≥80% to £2,017 (95% CI £1,507-2,526) for EDC adherence <50%.

      Conclusions

      This study provides a conservative estimate of excess inhaled medicines supply cost among adults with CF in the UK. The excess supply cost was highest among those with lowest EDC adherence, highlighting the importance of adherence support and supplying medicine according to actual use. MPR provides information about medicine supply but over-estimates actual medicine use.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Smith S
        • Rowbotham NJ
        • Regan KH.
        Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
        Cochrane Database Syst Rev. 2018; 3CD001021
        • Yang C
        • Montgomery M.
        Dornase alfa for cystic fibrosis.
        Cochrane Database Syst Rev. 2018; 9CD001127
        • Daniels T
        • Goodacre L
        • Sutton C
        • Pollard K
        • Conway S
        • Peckham D.
        Accurate assessment of adherence: self-report and clinician report vs electronic monitoring of nebulizers.
        Chest. 2011; 140: 425-432
      1. Hoo ZH, Totton N, Waterhouse S, et al. Real-world adherence among adults with cystic fibrosis is low – a retrospective analysis of the CFHealthHub digital learning health system. Chest Published Online First: 26 June 2021. doi: 10.1016/j.chest.2021.06.039.

        • Hoo ZH
        • Curley R
        • Walters SJ
        • Campbell MJ
        • Wildman MJ.
        Exploring the implications of different approaches to estimate centre-level adherence using objective adherence data in an adult cystic fibrosis centre – a retrospective observational study.
        J Cyst Fibros. 2020; 19: 162-167
        • Quittner AL
        • Zhang J
        • Marynchenko M
        • et al.
        Pulmonary medication adherence and health-care use in cystic fibrosis.
        Chest. 2014; 146: 142-151
        • White H
        • Shaw N
        • Denman S
        • Pollard K
        • Wynne S
        • Peckham DG.
        Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis.
        Eur Respir J. 2017; 491600987
      2. Trueman P, Lowson K, Blighe A, et al. Evaluation of the scale, causes and costs of waste medicines. Published November 2010. https://discovery.ucl.ac.uk/id/eprint/1350234/1/Evaluation_of_NHS_Medicines_Waste__web_publication_version.pdf. Date last accessed: December 18 2020.

      3. NHS England. PSS3 cystic fibrosis supporting self-care PSS CQUIN indicator. Published March 2019. https://www.england.nhs.uk/publication/pss3-cystic-fibrosis-self-care-pss-cquin-indicator/ . Date last accessed: December 18 2020.

        • Wildman MJ
        • O'Cathain A
        • Maguire C
        • et al.
        Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.
        Thorax Accepted:. 20 August 2021; https://doi.org/10.1136/thoraxjnl-2021-217594
        • Hollin IL
        • Donaldson SH
        • Roman C
        • et al.
        Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community.
        J Cyst Fibros. 2019; 18: 375-377
        • Rowbotham NJ
        • Smith S
        • Leighton PA
        • et al.
        The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.
        Thorax. 2018; 73: 388-390
        • Davies G
        • Rowbotham NJ
        • Smith S
        • et al.
        Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials.
        J Cyst Fibros. 2020; 19: 499-502
        • Hoo ZH
        • Edenborough FP
        • Curley R
        • et al.
        Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians’ decision.
        Eur J Clin Microbiol Infect Dis. 2018; 37: 735-743
        • Zhu VJ
        • Tu W
        • Rosenman MB
        • Overhage JM.
        A comparison of data driven-based measures of adherence to oral hypoglycemic agents in Medicaid patients.
        AMIA Annu Symp Proc. 2014; 2014: 1294-1301
        • Kozma CM
        • Dickson M
        • Phillips AL
        • Meletiche DM.
        Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.
        Patient Prefer Adherence. 2013; 7: 509-516
        • Sperber CM
        • Samarasinghe SR
        • Lomax GP.
        An upper and lower bound of the medication possession ratio.
        Patient Prefer Adherence. 2017; 11: 1469-1478
        • Eakin MN
        • Bilderback A
        • Boyle MP
        • Mogayzel PJ
        • Riekert KA.
        Longitudinal association between medication adherence and lung health in people with cystic fibrosis.
        J Cyst Fibros. 2011; 10: 258-264
        • Hoo ZH
        • Wildman MJ
        • Curley R
        • Walters SJ
        • Campbell MJ.
        Rescue therapy within the UK cystic fibrosis registry: an exploration of predictors of intravenous antibiotic use amongst adults with CF.
        Respirology. 2018; 23: 190-197
        • Zhang H
        • Bracken MB.
        Tree-based, two-stage risk factor analysis for spontaneous abortion.
        Am J Epidemiol. 1996; 144: 989-996
      4. UK Cystic Fibrosis Registry. Annual data report 2019. Published August 2020. https://www.cysticfibrosis.org.uk/the-work-we-do/uk-cf-registry/reporting-and-resources. Date last accessed: December 18 2020.

        • Burrows JA
        • Bunting JP
        • Masel PJ
        • Bell SC.
        Nebulised dornase alpha: adherence in adults with cystic fibrosis.
        J Cyst Fibros. 2002; 1: 255-259
        • Solé A
        • Gartner S
        • Alvarez A
        • et al.
        Adherence to the inhaled antibiotic treatment in patients with cystic fibrosis.
        Am J Respir Crit Care Med. 2013; 187: A4358
        • Siracusa CM
        • Ryan J
        • Burns L
        • et al.
        Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.
        J Cyst Fibros. 2015; 14: 621-626
        • Law AV
        • Sakharkar P
        • Zargarzadeh A
        • et al.
        Taking stock of medication wastage: unused medications in US households.
        Res Social Adm Pharm. 2015; 11: 571-578
        • Quittner AL
        • Modi AC
        • Lemanek KL
        • Ievers-Landis CE
        • Rapoff MA.
        Evidence-based assessment of adherence to medical treatments in pediatric psychology.
        J Pediatr Psychol. 2008; 33: 916-936
        • Durand H
        • Hayes P
        • Harhen B
        • et al.
        Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures.
        Br J Health Psychol. 2018; 23: 949-966
        • Conn VS
        • Ruppar TM.
        Medication adherence outcomes of 771 intervention trials: Systematic review and meta-analysis.
        Prev Med. 2017; 99: 269-276
        • Hoo ZH
        • Gardner B
        • Arden MA
        • et al.
        Role of habit in treatment adherence among adults with cystic fibrosis.
        Thorax. 2019; 74: 197-199
        • Dooney MK
        • Martin KJ
        • Iqbal N
        • Jones AM
        • Barry PJ.
        Home delivery influences medicines possession ratio in adult cystic fibrosis.
        Thorax. 2018; 73: A162-A163

      Linked Article